Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) is evaluating three potential locations in the United States for its planned integrated iodine and barium contrast drug manufacturing facility, the company announced June 18. The facility is designed to produce both iodinated and barium contrast agents from raw materials sourced domestically, aiming to create the first fully vertically integrated supply chain for these critical medical imaging drugs in North America.
The company is conducting a comprehensive analysis of candidate sites, focusing on proximity to iodine brine sources, logistics, infrastructure, access to skilled labor, and government incentive packages. Strong candidate locations have been identified in Oklahoma and Texas, with attributes including proximity to Voyageur’s iodine extraction initiatives in Oklahoma’s Anadarko Basin, robust transportation infrastructure, and competitive business climates. The final site will be selected based on the most attractive overall combination of factors, with a strong emphasis on incentive and support packages.
The facility will receive concentrated iodine liquor produced through Voyageur’s proprietary closed-loop Streamlined Iodine Process from its Oklahoma brine operations, together with high-purity barite from the Frances Creek project. Unlike conventional manufacturers that depend on imported iodine flakes or intermediates, this integrated GMP campus will combine on-site iodine-to-API synthesis with barite upgrading into USP-grade material and sterile injectable manufacturing. Management believes this will deliver the first fully domestic, vertically integrated supply chain for both iodinated and barium contrast agents at materially lower cost, with superior sustainability and supply security for U.S. hospitals and government customers.
Key anticipated project highlights include cost leadership through vertical integration, significant opportunities for U.S. federal and state funding and incentives, creation of 150–250 direct high-skilled jobs, and substantial economic activity and tax revenue. The facility is expected to support regional supply chains and enable efficient management of iodine and barium contrast production while supporting iodine supply for the company’s collaboration with Bayer on the Oklahoma iodine prill project.
Brent Willis, CEO of Voyageur Pharmaceuticals, stated: “This location decision optimizes logistics between our Oklahoma iodine sources and Canadian barite resources while providing the infrastructure required for GMP-compliant manufacturing. We are evaluating multiple strong jurisdictions and will select the site that delivers the most compelling overall package, including the strongest incentive support.” Site preparation and detailed engineering are targeted to commence in late 2026, with first production expected in Q4 2028–2029, subject to financing, regulatory approvals, and other customary conditions.
This announcement builds on Voyageur’s ongoing collaboration with Bayer and recent advancements in its barium contrast portfolio, including Health Canada-approved products already in commercial use. The company continues to work closely with economic development corporations and state and federal partners to advance incentives and permitting. Management believes the project aligns with U.S. priorities for domestic critical and strategic minerals, pharmaceutical onshoring of strategic drugs, and rural economic development.
